Health Canada approved the vaccine Covifenz in February of last year, after studies showed two doses were 71 per cent effective in protecting adults 18 to 64 against COVID-19 infection and disease. The vaccine was 70 per cent effective against Omicron.
The Medicago technology was also widely seen as having great potential for creating both vaccines and antibody treatments for other conditions, including cancers, arthritis and multiple sclerosis.
But the plants used in production are a cousin of the tobacco plant and were supplied by tobacco giant Phillip Morris, which was a minority (21 per cent) shareholder.
“It's well known the WHO and the UN have a very strict policy regarding engagement with the tobacco and arms industry, so the process is put on hold. It's very likely it won’t be accepted for emergency use listing," Mariangela Simao, a spokesperson for the WHO, said in a statement to CTV News Montreal at the time.
Without WHO’s endorsement, few governments were willing to buy the vaccine.
When it comes to vaccines, the WHO is interested in relative risks and the overall effect on the health of the population. When it comes to vaping, however, it cannot see beyond tiny – and largely hypothetical – absolute risks.
The Medicago technology was also widely seen as having great potential for creating both vaccines and antibody treatments for other conditions, including cancers, arthritis and multiple sclerosis.
Medicago had been preparing to launch full-scale production. However, its parent company, Mitsubishi Chemical Group, announced last week Medicago was closing down. Officials cited changes to the COVID-19 “vaccine landscape” and lower global demand for COVID-19 vaccines.
... That decision in Geneva effectively started the company on a death spiral, with the closure leading to 600 job losses.
No comments:
Post a Comment
Comments are only moderated after 14 days.